Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

The MASTER DAPT trial investigated the optimal duration of dual antiplatelet therapy (DAPT) in high-bleeding-risk patients after percutaneous coronary intervention (PCI) with a biodegradable-polymer sirolimus-eluting stent. Patients were randomized to either abbreviated DAPT (median 34 days) or standard DAPT (median 193 days). The study found that abbreviated DAPT was noninferior to standard DAPT for net adverse clinical events (7.5% vs. 7.7%) and major adverse cardiac or cerebral events (6.1% vs. 5.9%), while significantly reducing major or clinically relevant nonmajor bleeding (6.5% vs. 9.4%). These results suggest that shorter DAPT durations may be safe and effective for high-bleeding-risk patients post-PCI.

The MASTER DAPT trial investigated the optimal duration of dual antiplatelet therapy (DAPT) in high-bleeding-risk patients after percutaneous coronary intervention (PCI) with a biodegradable-polymer sirolimus-eluting stent. Patients were randomized to either abbreviated DAPT (median 34 days) or standard DAPT (median 193 days). The study found that abbreviated DAPT was noninferior to standard DAPT for net adverse clinical events (7.5% vs. 7.7%) and major adverse cardiac or cerebral events (6.1% vs. 5.9%), while significantly reducing major or clinically relevant nonmajor bleeding (6.5% vs. 9.4%). These results suggest that shorter DAPT durations may be safe and effective for high-bleeding-risk patients post-PCI.